Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Executive summary

Cretostimogene grenadenorepvec efficacy and safety

6 evidence topics · 36 sources

Summary: BOND-003 Cohort C, cretostimogene monotherapy in CIS-containing disease
  • Regulatory stage: cretostimogene is investigational, and the company states that its safety and efficacy have not been established by the FDA or any other health authority. The company initiated a rolling Biologics License Application (BLA) for cretostimogene monotherapy in high-risk BCG-unresponsive NMIBC in the fourth quarter of 2025 according to the Form 10-K and in November 2025 according to a Kissei release. In its PIVOT-006 topline release, the company stated that, based on FDA feedback, the initial BLA would be broadened to include high-grade papillary-only disease, with completion anticipated in March 2027.
  • Design and participants: Cohort C is a single-arm, open-label, phase 3 study in participants with BCG-unresponsive CIS with or without concomitant high-grade Ta/T1 papillary disease, done in 41 centres in North America, Asia, and Australia. Between October 9, 2020, and August 3, 2023, 165 participants were assessed for eligibility, 115 were enrolled, and 112 received cretostimogene as a 6-week induction followed by maintenance, with re-induction permitted for persistent disease at 3 months; 110 participants were efficacy evaluable. Responses were centrally confirmed, and bladder mapping at month 12 was mandatory.
  • Primary endpoint: complete response at any time was observed in 83 of 110 participants (75.5%; 95% CI 66.3% to 83.2%) as of the June 23, 2025 data cutoff, at a median follow-up of 25.8 months (IQR 22.1 to 33.1). The company states that the cohort “met its primary endpoint with statistical significance”.
  • Landmark complete response: 46.4% at 12 months (51 of 110; 95% CI 36.9 to 56.1 on the SUO 2025 poster and 36.8 to 56.1 in a 2026 presentation) and 41.8% at 24 months (46 of 110; 95% CI 32.5 to 51.6).
  • Durability: median duration of response was 27.9 months (95% CI 14.3 to not estimable) and ongoing. The estimated duration of response at 12 and 24 months was 64.2% (95% CI 52.2 to 73.8) and 60.1% (95% CI 48.2 to 70.0) in a 2026 presentation and the company's 2026 publication release; the company's September 2025 release and one passage of the Form 10-K give 64.1% and 58.3% for the same cutoff, the values a 2025 presentation reported at the March 14, 2025 cutoff. Of participants re-induced, 50.0% converted to complete response.
  • Progression and cystectomy: 106 of 110 participants (96.4%) were free from progression to T2 or higher disease in a 2026 presentation; the company's 2026 publication release states 96.6% at 48 and 96 weeks and that 3.4% progressed. Kaplan-Meier cystectomy-free survival was 89.2% (95% CI 81.3 to 93.9) at 12 months and 81.3% (95% CI 71.8 to 87.8) at 24 months in one presentation, and a 2026 translational presentation gives 85% at 24 months. Eighteen participants underwent radical cystectomy after recurrence (12) or progression (6).
  • Safety (112 participants): 71 (63.4%) had at least one treatment-related adverse event (TRAE), most often bladder spasm (28; 25.0%), pollakiuria (25; 22.3%), urgency (23; 20.5%), dysuria (21; 18.8%), and hematuria (15; 13.4%). No grade 3 or higher TRAEs, treatment-related discontinuations, or treatment-related deaths occurred, and the median time to TRAE resolution was 1 day. Two participants (1.8%) had serious grade 2 TRAEs: non-infective cystitis and, depending on the source, urinary bladder haemorrhage (publication) or clot retention (2026 presentation and Form 10-K). No health-related quality of life results were identified.
Summary: BOND-003 Cohort P, cretostimogene monotherapy in papillary-only disease
  • Design and role: Cohort P is a single-arm, open-label cohort of BOND-003 in participants with BCG-unresponsive high-grade Ta/T1 papillary disease without CIS, with a registry target of up to 75 participants. The Form 10-K describes it as “Phase 3” and as “an exploratory study”, and the 2026 investor presentation as “a Phase 2 cohort of BOND-003 and currently not intended for regulatory approval”; in its PIVOT-006 topline release the company stated that the initial BLA would be broadened to include high-grade papillary-only disease. Enrollment began in March 2024 according to a 2025 congress presentation; the Form 10-K and Form 10-Q state that the cohort was initiated in April 2024.
  • Participants: at the September 1, 2025 data cutoff, 56 participants were in the safety dataset and 51 were efficacy evaluable at a median follow-up of 6.0 months; the 2026 investor presentation lists an efficacy population of “N=54”. Tumor stage at entry was 33 high-grade Ta and 23 high-grade T1 in the SUO 2025 presentation and 37 and 19 in a 2026 poster that also reports 11 participants re-induced, against 8 re-induced at 3 months in another 2026 poster. Of participants, 96.4% were enrolled in the US.
  • Primary endpoint: the registry and congress presentations name high-grade event-free survival (HG-EFS); one passage of the Form 10-K names “overall event-free survival”. Kaplan-Meier estimates of HG-EFS were 95.7% (95% CI 83.8 to 98.9) at 3 months, 84.6% (95% CI 68.6 to 92.9) at 6 months, and 80.4% (95% CI 62.3 to 90.4) at 9 months, with 5 censored participants pending efficacy assessment; the SUO 2025 slide labels the same estimates high-grade recurrence-free survival. The 12-month estimate was “Not Yet Reached” in the 2026 investor presentation, and the third-quarter 2026 results release expects 12-month data in December 2026.
  • Progression and cystectomy: no participant underwent radical cystectomy or progressed to muscle-invasive disease, and 1 participant progressed to metastatic urothelial carcinoma despite a clinical complete response in the bladder.
  • Safety (56 participants, September 1, 2025 cutoff): 40 (71.4%) had at least one TRAE, most often bladder spasm (26; 46.4%), dysuria (22; 39.3%), pollakiuria (14; 25.0%), and urgency (11; 19.6%). No grade 3 or higher TRAEs, serious TRAEs, deaths, treatment-related discontinuations, or dose delays or missed doses due to TRAEs were reported. The Form 10-K also lists hematuria among the most common TRAEs (10% or more).
Summary: CORE-001, cretostimogene with pembrolizumab
  • Design and participants: CORE-001 is an open-label, single-group phase 2 study of intravesical cretostimogene with intravenous pembrolizumab in participants with BCG-unresponsive NMIBC with CIS with or without Ta/T1 papillary disease, with Merck Sharp & Dohme LLC as collaborator. It started on December 8, 2020, at 19 locations. Thirty-five participants were treated, 30 (85.7%) in the USA and 5 (14.3%) in Korea. Cretostimogene was given weekly for 6 weeks, then as three weekly maintenance instillations at months 3, 6, 9, 12, and 18 in participants maintaining complete response, and pembrolizumab for up to 24 months.
  • Primary endpoint: complete response at 12 months, assessed with mandatory bladder mapping biopsies, was 57.1% (20 of 35; 95% CI 40.7% to 73.5%) in the publication, meeting the primary endpoint. The company reports the same 20 of 35 with a 95% CI of 40% to 73% (February 5, 2024 cutoff, press release) and 39.5% to 73.2% (May 17, 2024 cutoff, Form 10-K).
  • Other efficacy outcomes: 29 of 35 participants (82.9%; 95% CI 70.4% to 95.3%) had a complete response at 3 months. At a median follow-up of 26.5 months, median duration of response was not reached (95% CI 15.7 to not reached). Complete response at 24 months was 51.4% (18 of 35; 95% CI 34.9% to 68.0%) in the publication and 54% (19 of 35; 95% CI 37% to 71%) at the May 17, 2024 cutoff in the company press release (54.3%, 95% CI 36.9% to 70.8%, in the Form 10-K). No participant progressed to muscle-invasive bladder cancer, and the company reports cystectomy-free survival of 80% at 24 months.
  • Safety (35 participants): 32 (91.4%) had at least one study drug-related adverse effect and 5 (14.3%) had grade 3 treatment-related adverse effects; the most common were bladder spasm (17; 48.6%), fatigue (13; 37.1%), dysuria (9; 25.7%), and pollakiuria (9; 25.7%). The publication table states that there were no grade 3 to 5 cretostimogene-related adverse effects; an author correction removed abstract statements attributing immune-related adverse effects exclusively to pembrolizumab and states that attribution was “assessed by the treating physicians”.
Summary: BOND-002, cretostimogene monotherapy after BCG failure
  • Design and participants: BOND-002 was an open-label, single-arm, phase 2 study of CG0070 in participants with high-grade NMIBC who had failed BCG and refused cystectomy, started on June 2, 2015, at 17 locations. The registry lists 66 participants enrolled; the Form 10-K reports 65 (46 with CIS with or without Ta/T1 disease and 19 with Ta/T1 disease) and describes the population as “a heterogenous mixture of BCG-exposed and BCG-unresponsive NMIBC”. The registered primary endpoint is the proportion of participants with a durable complete response lasting 12 months or longer and assessed at 18 months; no result for it was identified.
  • Efficacy: at the April 2017 interim analysis of 45 participants with evaluable 6-month follow-up, complete response at 6 months was 47% (95% CI 32% to 62%): 58% (37% to 78%) for pure CIS, 50% (33% to 67%) for CIS with or without Ta/T1, and 33% (8% to 70%) for pure Ta/T1. The Form 10-K reports complete response at any time in 40 participants (61.5%), with median duration of response not reached after 18 months, and in 30 of 46 participants (65.2%; 95% CI 49.7% to 78.2%) with CIS-containing disease; the 2024 prospectus gives 65% (95% CI 50% to 78%) for the same 30 of 46 and reports 44% and 28% of patients with complete response at 6 and 12 months.
  • Safety: at 6 months the most common TRAEs were bladder spasms (36%), hematuria (28%), dysuria (25%), and urgency (22%), with flu-like symptoms (12%) and fatigue (6%). Grade 3 TRAEs were dysuria (3%) and hypotension (1.5%), with no grade 4 or 5 TRAEs, and the Form 10-K reports eight serious adverse events determined not related to cretostimogene.
Summary: V-0046, phase 1 dose escalation
  • Design and participants: V-0046 was a non-randomized, open-label, phase 1 dose-escalation study of intravesical CG0070 in bladder cancer after BCG failure, with a registered primary endpoint of the maximum tolerated or maximum feasible dose. Thirty-five participants received single or multiple (every 28 days × 3 or weekly × 6) infusions at 1 of 4 dose levels, from 1 × 10^12 to 3 × 10^13 viral particles. A maximum tolerated dose was not reached.
  • Efficacy: the 2012 publication reports a complete response rate of 48.6% across cohorts with a median duration of 10.4 months, and 63.6% (14 of 22) in the multidose cohorts. A 2010 congress report gives a complete response rate of 46% for all participants. A 2023 company presentation gives complete response at 3 months in 16 of 35 participants (46%), 13 of 22 (59%) on multi-dose schedules, and 7 of 9 (78%) on the weekly × 6 schedule, with a median duration of 8.4 months.
  • Safety: grade 1 to 2 bladder toxicities were the most common adverse events. The 2010 congress report states that no serious adverse events and one dose-limiting toxicity (grade 3 lymphopenia) were reported, and that flu-like illness occurred in 10% to 20% of participants.
Summary: safety across studies
  • Monotherapy in BOND-003: TRAEs occurred in 71 of 112 participants (63.4%) in BOND-003 Cohort C (June 23, 2025 cutoff) and 40 of 56 (71.4%) in Cohort P (September 1, 2025 cutoff), with no grade 3 or higher TRAEs and no treatment-related discontinuations in either cohort. Serious TRAEs occurred in 2 participants (1.8%, both grade 2) in Cohort C and none in Cohort P.
  • Most frequent TRAEs: bladder spasm occurred in 25.0% of Cohort C, 46.4% of Cohort P, and 36% of the BOND-002 interim population; dysuria in 18.8%, 39.3%, and 25%; and urgency in 20.5%, 19.6%, and 22%, respectively. In Cohort C the median time to TRAE resolution was 1 day.
  • Earlier monotherapy studies: BOND-002 reported grade 3 dysuria (3%) and hypotension (1.5%) and no grade 4 or 5 TRAEs; V-0046 reported one dose-limiting grade 3 lymphopenia, did not reach a maximum tolerated dose, and reported flu-like illness in 10% to 20% of participants (12% with flu-like symptoms in BOND-002).
  • Combination with pembrolizumab: in CORE-001, 32 of 35 participants (91.4%) had a study drug-related adverse effect and 5 (14.3%) had a grade 3 treatment-related adverse effect, with no grade 3 to 5 adverse effects attributed to cretostimogene.
  • BOND (NCT01438112), registered as an open-label, randomized phase 2/3 study, enrolled 22 participants and lists “Change in study design” as its reason for stopping; no efficacy or safety results for it were identified.